Athenex Story

<div class='circular--portrait' style='background:#FF0000;color: #F8F8FF;font-size:3em;'>ATN</div>
ATNX -- USA Stock  

USD 4.11  0.01  0.24%

Athenex Net Cash Flow or Change in Cash and Cash Equivalents is fairly stable at the moment as compared to the past year. Athenex reported Net Cash Flow or Change in Cash and Cash Equivalents of 89.11 Million in 2020. Issuance Repayment of Debt Securities is likely to rise to about 6.5 M in 2021, whereas Net Income Per Employee is likely to drop (206.8 K) in 2021. As many investors are getting excited about healthcare space, it is fair to break down Athenex. We will evaluate why we are still optimistic in anticipation of a recovery. This post is to show some fundamental factors affecting Athenex's products and services. I will also show how it may impact the investing outlook for Athenex in March.
Published over a month ago
View all stories for Athenex | View All Stories
Athenex is gently turning things around for investors
About 20.0% of Athenex shares are held by company insiders. Insiders ownership of Athenex refers to the amount of Athenex equity owned by Athenex officers, directors, relatives of the leadership team, or anyone who has access to private information before it's made available to the public. Check out our latest analysis of Athenex, including its current ownership diagnostics.

How important is Athenex's Liquidity

Athenex financial leverage refers to using borrowed capital as a funding source to finance Athenex ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Athenex financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between Athenex's total debt and its cash.

What do experts say?

Stock analysis is a method for investors and traders to make buying and selling decisions. By studying and evaluating past and current data, investors and traders attempt to gain an edge in the markets by making informed decisions.
It is good to see analyst projects for Athenex, but it might be worth checking our own buy vs. sell analysis

Athenex exotic insider transaction detected

Legal trades by Athenex insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
Athenex insider trading alert for general transaction of stock option (right to buy) by Kim Campbell, the corporate stakeholder, on 7th of April 2021. This event was filed by Athenex Inc with SEC on 2021-04-07. Statement of changes in beneficial ownership - SEC Form 4 [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

Breaking it down a bit more

Athenex retains a total of 93.34 Million outstanding shares. Over half of Athenex outstanding shares are owned by other corporate entities. These other corporate entities are typically referred to corporate investors that acquire positions in a given instrument to benefit from reduced trade commissions. Consequently, these institutions are subject to different rules and regulation than regular investors in Athenex. Please watch out for any change in the institutional holdings of Athenex as this could mean something significant has changed or about to change at the company. Remember, it does not matter who owns the company or if the company is currently losing money. If the true value of the company is more than the market pays for it currently, you can still have a good investment opportunity.

Ownership Breakdown

Retail Investors
21.53%
Insiders
19.52%
Institutions
58.95%
Retail Investors21.53
Insiders19.52
Institutions58.95

Possible March correction of Athenex?

Athenex current kurtosis rises over 0.17. Athenex exhibits very low volatility with skewness of 0.63 and kurtosis of 0.17. However, we advise investors to further study Athenex technical indicators to make sure all market info is available and is reliable. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Athenex's stock risk against market volatility during both bullying and bearish trends. The higher level of volatility that comes with bear markets can directly impact Athenex's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different stocks as prices fall.

Our Final Take On Athenex

While some firms within the drug manufacturers?specialty & generic industry are still a little expensive, even after the recent corrections, Athenex may offer a potential longer-term growth to investors. To conclude, as of the 28th of February 2021, our current 30 days buy-sell recommendation on the company is Strong Hold. We believe Athenex is undervalued with below average odds of financial distress for the next two years.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Achuva Shats do not own shares of Athenex. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com